A review of the latest decisions regarding the SPC waiver and its impact upon your generic and innovator life science exclusivity strategy.
Discover the intersection between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a Tecfidera case law review and the Pharmaceutical Strategy for Europe.
Understand the requirements for patentability within the life sciences industry with panel sessions on patent quality, G2/21, enablement and the PTAB.
Discuss the ways in which the UPC is impacting your life science strategy with an industry-led session and judges panel.
Over 65 In-House and Private Practice speakers are confrimed in this jam packed agenda